Topics

Roche's Tecentriq, a PD-L1, Approved in China for Small Cell Lung Cancer

02:49 EST 15 Feb 2020 | ChinaBio Today

Roche announced China approval to launch its PD-L1 immunotherapy, Tecentriq (atezolizumab). Tecentriq is approved in combination with chemotherapy (carboplatin and etoposide) as a a first-line treatment for extensive-stage small cell lung cancer (ES-SCLC). Roche noted the China approval came less than a year after Tecentriq was approved in the US and EU. One month ago, the China NMPA also accepted for review a supplemental Tecentriq BLA in combination with Avastin to treat unresectable hepatocellular carcinoma. More details....

Stock Symbol: (SIX: ROG)

Share this with colleagues:

Original Article: Roche's Tecentriq, a PD-L1, Approved in China for Small Cell Lung Cancer

NEXT ARTICLE

More From BioPortfolio on "Roche's Tecentriq, a PD-L1, Approved in China for Small Cell Lung Cancer"

Quick Search

Relevant Topic

Immunology
Allergies Automimmune Disease Human Papillomavirus (HPV) Immunology Vaccine Immunology is the study of immunity and the defence mechanisms of the body. A greater understanding of immunology is needed to develop vaccines, understand ...